1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A.

1,168.50
MXN
-0.36
(-0.03%)
72.21EPS
16.22P/E
59.94BMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.37
4.78
4.97
5.38
5.59
5.92
6.91
7.58
11.71
15.29
16.01
14.93
14.54
15.11
Basic EPS, GAAP
0.46
0.48
0.4
0.53
0.35
0.35
0.71
1.1
2.76
3.73
3.29
2.68
2.75
3.62
Free Cash Flow per Basic Share
0.1
-0.04
0.19
0.56
-0.04
-0.35
-0.9
0.13
1.96
3.48
1.12
1.49
2.33
3.44
Dividend per Share
0.14
0.16
0.17
0.14
0.18
0.12
0.08
0.18
0.38
0.95
1.33
1.1
0.94
- -
Book Value per Share
2.89
3.19
3.34
3.72
3.89
5.19
5.82
6.75
8.59
9.93
10.41
11.18
12.99
13.7
Tangible Book Value per Share
2.6
2.84
2.96
3.22
3.34
4.57
5.01
6
7.89
9.25
9.75
10.52
12.29
13
Basic Weighted Avg Shares
50
50
50
49
49
51
55
55
55
53
52
51
51
51
Sales/Revenue/Turnover
218
238
246
265
276
303
381
420
649
818
830
764
743
773
Operating Margin (%)
11.71
11.63
8.88
10.67
6.9
5.76
11.33
18.44
27.98
31.29
26.55
23.51
24.99
22.72
Depreciation Expense
7
9
10
11
11
12
18
20
21
23
24
28
30
34
Net Income, GAAP
23
24
20
26
17
18
39
61
153
200
170
137
140
185
Effective Tax Rate (%)
5.07
5.92
5.21
6.43
1.6
- -
6.22
15.88
16.18
22.6
22.73
22.97
23.41
21.33
Profit Margin (%)
10.58
10.13
8.05
9.84
6.25
5.9
10.3
14.54
23.6
24.42
20.53
17.92
18.89
23.95
Working Capital
79
100
95
91
95
166
211
242
316
329
309
333
385
291
LT Debt
23
32
33
21
27
17
72
68
67
59
52
91
93
81
Total Equity
144
158
165
183
192
287
322
374
471
521
543
582
675
717
Return on Invested Capital (%)
14.21
14.07
10.29
12.47
8.27
- -
11.03
14.7
30.65
34.79
28.18
21.07
18.98
23.99
Return on Capital (%)
14.36
14.2
10.69
12.69
8.07
- -
10.94
14.45
31
35.19
28.42
21.22
19.09
24.66
Return on Common Equity (%)
17
15.92
12.26
14.99
9.19
7.47
12.88
17.54
36.25
40.3
32.16
24.63
22.72
29.3

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
29
28
27
LT Borrowings
84
- -
- -
LT Finance Leases
9
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
3,147
4,154
3,003

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
567
539
568
Cash, Cash Equivalents & STI
98
97
128
Accounts Receivable, Net
163
164
148
Inventories
288
274
273
Total Current Liabilities
181
148
277
Payables & Accruals
- -
- -
- -
ST Debt
29
28
27
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.8%
12.82%
16.15%
Free Cash Flow
248.63%
300.18%
56.81%
Net Income, GAAP
32.59%
29.88%
2.6%
Sales/Revenue/Turnover
12.9%
14.28%
-2.65%
Total Cash Common Dividend
33.45%
52.22%
-15.27%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
151
178
235
434
764
2025
155
160
210
218
743
2026
152
192
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.55
1.36
1.81
2.68
2025
0.35
0.42
1.13
0.83
2.75
2026
0.19
1.47
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.1
2025
- -
- -
- -
- -
0.94
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Juan López-Belmonte Encina
Full Time Employees
2,232
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Calle José Isbert, 2 Madrid Spain 28223
IPO Date
Nov 15, 2007
Website
rovi.es
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. It operates through the following business segments: Manufacturing, Marketing, and Other. The Manufacturing segment obtains its income from service contracts that relate to the finalization of the pharmaceutical product production process for external entities and the manufacture of products to be subsequently marketed by other group companies. The Marketing segment purchases and sells pharmaceutical products. The Other segment includes other services, research, and development activities that are not significant for the group. The company was founded on December 21, 1946 and is headquartered in Madrid, Spain.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Laboratorios Farmaceuticos Rovi, S.A. (LABFF) 2024 Financial Results Earnings Call Transcript